- Home
- CAPT vs NCNA Comparison
CAPT vs NCNA Comparison
Compare CAPT & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAPT | NCNA |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | South Korea | United Kingdom |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 13.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CAPT | NCNA |
|---|---|---|
| Price | $0.39 | $3.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 58.1K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,389,944.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 84.70 | N/A |
| 52 Week Low | $0.30 | $2.78 |
| 52 Week High | $1.94 | $268.00 |
Technical Indicators
Market Signals| Indicator | CAPT | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 40.60 |
| Support Level | $0.36 | $3.50 |
| Resistance Level | $0.58 | $3.77 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 33.94 | 38.71 |
Price Performance
Historical ComparisonAbout CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.